🔗 Share this article

An underground market for unlicensed weight-loss drugs is being driven by TikTok fitness influencers and sellers on communication apps, based on recent findings.

Experimental Treatment Acquiring Popularity Via Social Media

The experimental drug, which remains in clinical trials, is being advertised by online personalities for its alleged weight-reducing effects. Followers are encouraged to contact these accounts directly for supplier links, while also receiving discount codes.

Active Commerce on Messaging Platforms

Additionally, a robust market exists on messaging services, where groups with thousands of participants share comparison images, administration instructions and claims of rapid British shipping. Vendors market the substance there before redirecting customers to other platforms for purchases.

Understanding Retatrutide

Retatrutide is an investigational injectable developed by US drugmaker Eli Lilly. The treatment affects three gut hormones – GLP-1, GIP and pancreatic hormone. Preliminary studies indicate it could help individuals reduce up to a quarter of their body weight. Nicknamed the “triple G”, the drug is being promoted digitally as the next Ozempic.

Medical Professionals Express Concerns

Nevertheless, physicians and chemists have warned that the sale of what remains an unapproved medication in the United Kingdom is worrisome and could result in users administering substances of unknown origin.

Some professionals stated the demand for the experimental drug could be connected to the increasing cost of licensed weight loss products such as Mounjaro.

Legal Status and Implementation

Selling the unapproved drug on social media or Telegram is prohibited in the UK, as it is an unlicensed drug that must not be marketed or distributed for human use under the Human Medicines Regulations 2012.

Several content creators attempt to sidestep the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and supply can still violate medicines, marketing, and consumer laws, potentially leading to fines, prosecution or prison.

Platform Reaction and Content Elimination

Based on TikTok, the service has taken down problematic content and banned related keywords and query recommendations. The company said it was dedicated to maintaining the service safe and investing in enhancing enforcement strategies.

Digital Marketplace Operations

Investigations also found groups with up to 9,000 participants selling retatrutide using the platform's integrated search feature, which operates like a public directory. Entering “retatrutide” instantly displays channels with numerous of members, filled with images of weight loss, glowing reviews and step-by-step instructions for mixing or administering at residence.

After minutes of joining one community, a vendor shared contact information, where most transactions take place. The seller sent an instruction manual and promised delivery within two days. When questioned whether the product was authentic, one vendor said: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. Not one inquired about body mass, health issues or previous experience.

Product Information and Costs

Within these groups, messages display black plastic packages with postal service stickers, claiming to contain new batches. One message stated: “It took eight of us to load them this morning.”

Buyers can select between powder vials, mixed at home with sterile water, or ready-to-use pens typically priced at 160 pounds for 20 milligrams. When questioned how long a pen should last, vendors give conflicting answers varying between a several days to “depends on your body”.

Platform Oversight and Security Actions

A representative for Telegram stated it actively moderated dangerous material on its service including content that encouraged the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Medical Professional Cautions

“Individuals are administering materials they can’t verify. Although the research behind this drug is sound, these digital versions may not include what they claim,” said Jason Murphy, the director of pharmaceutical services at a pharmacy service.

A medical professional of Asda Online Doctor connected the surge in demand to recent price rises for approved weight-loss medications such as Mounjaro. “With costs increasing, individuals are turning to online platforms. But counterfeit injections are extremely risky. You cannot know what’s contained or whether the conditions they were made in was sterile,” she said.

Her staff has previously encountered individuals injured by self-injection from unverified suppliers. “We understand the frustration, but purchasing from Telegram or communication platforms is taking chances with your health,” stated the doctor. “These materials could be contaminated or improperly measured.”

Manufacturer Position

A representative from the pharmaceutical company said the substance was in phase 3 research studies and had not been reviewed or authorized by any government authority globally. “Therefore at this point no one can market [it] for personal consumption,” they said, adding that any product “misleadingly claiming itself as a Lilly investigational substance not yet approved … may subject patients to possibly serious health risks”.